[Protective effects of incretin on atherosclerosis].
Type 2 diabetes is a major risk factor for atherosclerotic disease. Thus, the one of the therapeutic goal is to prevent the progression of atherosclerosis in these patients. Recently, exogenous administration of glucagon-like peptide-1 (GLP-1) or GLP-1 receptor agonist has direct beneficial effects on vascular cells such as endothelial cell, monocyte/macrophage and vascular smooth muscle cells independent of their glucose lowering effects. These data highlight the potential protective effects of GLP-1 on the progression of atherosclerosis. However, further experimental study is needed to clarify the mechanism of these effects on vascular cells with GLP-1 and large clinical trial is also required to assess whether GLP-1 could reduce the cardiovascular events in patients with type 2 diabetes.